|
|
Human Genome Sciences Inc - Comparative Business Analysis Snapshot
Business Description
Human Genome Sciences Inc. The Group's principal activities are to develop, manufacture and market human protein and antibody drugs. The products of the Group are clinical development for chronic hepatitis C, LymphoStat-B(R) for systemic lupus erythematosus and ABthraxtm for inhalation anthrax. The Clinical development includes drugs to treat diseases like cancer, rheumatoid arthritis, lupus, hepatitis C, anthrax disease and HIV. It also has a portfolio of novel drugs in earlier stages of development, led by our TRAIL receptor antibodies in mid-stage development for cancer and including substantial financial rights to three novel drugs in the GlaxoSmithKline (GSK) clinical pipeline. It is developing Syncria as a treatment for type 2 diabetes mellitus. Syncria is generated from the genetic fusion of human albumin and GLP-1.
Competitor Analysis
This analysis compares Human Genome Sciences Inc with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
